文献速递血栓与止血

罗米司亭在儿科临床试验及全球上市后登记中的免疫原性评估

Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.
PubMed 文献 · Blood Adv · 2021-01-01

该研究评估了儿童原发免疫性血小板减少症(ITP)患者使用罗米司亭后抗药抗体和抗TPO抗体的发生情况。在5项临床试验中,280例患者中8.9%出现抗罗米司亭结合抗体,2.9%出现中和抗体,多数抗体阳性患者仍维持血小板应答;上市后登记中结合抗体和中和抗体发生率分别为15.8%和5.3%。结果表明罗米司亭在儿童ITP中免疫原性少见,且通常不伴血小板应答丧失。

要点

  • 儿童ITP临床试验中抗罗米司亭结合抗体发生率8.9%,中和抗体2.9%。
  • 多数产生中和抗体患者仍维持血小板应答,未见TPO交叉反应。
  • 上市后登记抗体发生率略高,但样本量小,需谨慎解读。

核心结论

  • 罗米司亭在儿童ITP患者中免疫原性不常见,且一般不与血小板应答丧失或其他不良临床后果相关。

研究设计与样本

  • 研究分析了5项临床试验和一项全球上市后登记中儿童原发ITP患者抗罗米司亭及抗TPO抗体发生情况。
  • 临床试验共纳入280例患者进行抗体检测,上市后登记纳入19例患者。

主要发现

  • 临床试验中25/280(8.9%)患者出现抗罗米司亭结合抗体,首次阳性中位时间为开始治疗后67周。
  • 8/280(2.9%)患者出现抗罗米司亭中和抗体,其中7/8(88%)仍有血小板应答。
  • 9/279(3.2%)患者出现抗TPO结合抗体,1/279(0.4%)出现一过性抗TPO中和抗体。
  • 8例产生抗罗米司亭中和抗体的患者中未观察到TPO交叉反应。
  • 上市后登记中3/19(15.8%)出现抗罗米司亭结合抗体,1/19(5.3%)出现中和抗体。

临床怎么用

  • 儿童ITP患者使用罗米司亭时免疫原性风险较低,多数抗体阳性者仍可维持血小板应答。

局限性

  • 上市后登记样本量较小(19例),抗体发生率估计可能不稳定。
  • 临床试验中抗体检测及随访方案可能影响免疫原性检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of first-generation thrombopoietins (TPOs) was halted due to antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some patients. The second-generation TPO receptor agonist romiplostim, having no homology to TPO, was developed to circumvent potential immunogenicity. We examined the development of binding and neutralizing antibodies to romiplostim and TPO among pediatric patients with primary immune thrombocytopenia (ITP) in 5 clinical trials and a global postmarketing registry. In the trials, 25 of 280 (8.9%) patients developed anti-romiplostim binding antibodies. The first positive result was detected 67 weeks (median) after romiplostim treatment was initiated. The median romiplostim dose was 8 µg/kg, and the median platelet count was 87 × 109/L. Most patients who developed anti-romiplostim binding antibodies (18 of 25 [72%]) had ≥90% of platelet assessments showing a response. Anti-romiplostim neutralizing antibodies developed in 8 of 280 (2.9%) patients. The development of anti-romiplostim neutralizing antibodies was unrelated to the romiplostim dose, and most patients who developed the antibodies (7 of 8 [88%]) had platelet response. Nine of 279 (3.2%) patients developed anti-TPO binding antibodies, and 1 (0.4%) developed transient anti-TPO neutralizing antibodies. In 8 patients who developed anti-romiplostim neutralizing antibodies, no TPO cross-reactivity was observed. In the postmarketing registry, 3 of 19 (15.8%) patients developed anti-romiplostim binding antibodies; 1 (5.3%) patient developed anti-romiplostim neutralizing antibodies. These results suggest that immunogenicity to romiplostim occurs infrequently in pediatric patients with ITP and is generally not associated with loss of platelet response or other negative clinical sequelae.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bowers C, Mytych DT, Lawrence T, et al. Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. Blood Adv. 2021. PMID: 34638135. doi:10.1182/bloodadvances.2021005105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。